International Journal of Environmental Research and Public Health 2023
Surowiecka A et al. Multidisciplinary Treatment in Toxic Epidermal Necrolysis
PMID 36767584
Nutrition, wound care, and supportive management
Prognostic and treatment trials
JAMA Dermatology 2022
Koh HK et al. Improvement of Mortality Prognostication — Re-SCORTEN
SCORTEN validation and revision with novel inflammatory markers
Koh HK et al. Assessment and Comparison of ABCD-10 and SCORTEN 2020
ABCD-10 performance versus SCORTEN comparison
Cochrane Database 2022
Jacobsen A et al. Systemic Interventions for Treatment of SJS/TEN
No definitive evidence for any single systemic immunomodulatory agent
Journal of the German Society of Dermatology (JDDG) 2025
Heuer R et al. Systemic Immunomodulating Therapies for Epidermal Necrolysis
Cyclosporine: RR 0.18 vs. IVIG; etanercept: RR 0.32 vs. supportive care
JAMA Dermatology 2025
Chiu HY, Chiu YM. Risk of Cardiovascular Morbidity and Mortality in SJS/TEN Survivors
Long-term cardiovascular outcomes data
Campbell CN et al. HLA-B*58:01 and Risk of Allopurinol-Induced Severe Cutaneous Adverse Reactions in the US
Ocular and genetic references
Allergology International 2025
Sotozono C, Ueta M. Updates on Ocular Manifestations and Treatment of SJS/TEN
Amniotic membrane transplantation within 72 hours evidence
Genetics in Medicine 2022
Tayeh MK et al. Clinical Pharmacogenomic Testing (ACMG)
HLA screening guidelines for carbamazepine and allopurinol
JAMA Dermatology 2021
Hoffman M et al. Long-term Physical and Psychological Outcomes of SJS/TEN
PTSD 30–50% prevalence, chronic ocular sequelae data
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.